Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.

Scroll to Top